The role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer.
- Author:
Cheng-feng WANG
1
;
Ping ZHAO
;
Yi SHAN
;
Dong-bing ZHAO
;
Yan-tao TIAN
;
Xiao-feng BAI
;
Yue-min SUN
;
Xu CHE
;
Hui QU
;
Yi-bin XIE
Author Information
- Publication Type:Journal Article
- MeSH: Antimetabolites, Antineoplastic; administration & dosage; therapeutic use; Drug Implants; adverse effects; Female; Fluorouracil; administration & dosage; therapeutic use; Follow-Up Studies; Humans; Male; Microspheres; Middle Aged; Neoplasm Staging; Pancreatic Fistula; etiology; Pancreatic Neoplasms; drug therapy; pathology; Prospective Studies; Remission Induction; Survival Rate
- From: Chinese Journal of Oncology 2010;32(9):706-708
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the role of slow-release 5-fluorouracil implantation in treatment of unresectable pancreatic cancer.
METHODS85 cases of untreated patients with locally advanced pancreatic cancer (LAPC) were randomized into two groups: Trial group: slow-release 5-fluorouracil implantation (50 patients) and control group (35 patients). Observing the objective tumor response, clinical benefit response, toxicity, complications and survival of patients of the two groups.
RESULTSIn the trial group the overall response rate (PR + NC) was 76.0%, and the clinical benefit response rate was 52.0%. No toxicity was observed. Pancreatic fistula occurred in 2 patients. The median survival time of the two groups was 9.0 months and 4.0 months, respectively. The survival rates of 6- and 12-month were 56.8% vs. 31.4% and 22.9% vs. 2.9% in the two groups, respectively (P = 0.012).
CONCLUSIONSlow-release 5-fluorouracil implantation is a simple, safe and effective method in treatment of LAPC.
